Sign In
Buy BNTX
$88.45
-0.690 (-0.774%)
At Close: Jun 03, 2026
MAINZ, Germany, and PRINCETON, USA, June 2, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced that the companies have entered into
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
08:15am, Tuesday, 27'th May 2025
MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company's diversified onc
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots
09:41am, Wednesday, 21'st May 2025
Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.
BioNTech plans up to $1.33 billion investment in the United Kingdom
09:09am, Tuesday, 20'th May 2025
German vaccine maker BioNTech said on Tuesday that it plans to invest up to 1 billion pounds ($1.33 billion) over the next ten years to broaden its research and development activities in the United Ki
New vaccine chief rocks pharmaceutical stocks
11:13am, Wednesday, 07'th May 2025
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
Why BioNTech Stock Got Trounced on Tuesday
06:15pm, Tuesday, 06'th May 2025
An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (BNTX -6.58%). Investors were concerned about the latest top-level
BioNTech: mRNA Challenges Amid Regulatory Uncertainty (Rating Downgrade)
07:45am, Tuesday, 06'th May 2025
BioNTech maintains strong cash reserves (€15.85B) despite widening losses as COVID revenues decline and R&D expenses increase. BNT327 (PD-L1/VEGF-A bispecific) advances to Phase 3 trials, but shares
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
03:49pm, Monday, 05'th May 2025
BioNTech SE BNTX on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02.
BioNTech SE (BNTX) Q1 2025 Earnings Call Transcript
11:39am, Monday, 05'th May 2025
BioNTech SE (NASDAQ:BNTX ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder & Chief Executive Office
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update
06:45am, Monday, 05'th May 2025
Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A 1 , and mRNA
BioNTech says Novartis executive Zapata-Gomez to become CFO
06:34am, Monday, 05'th May 2025
German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.
BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer
06:30am, Monday, 05'th May 2025
Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Man
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
05:05pm, Friday, 25'th Apr 2025
Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (SMMT -36.19%) and BioNTec
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025
06:45am, Thursday, 24'th Apr 2025
MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer
BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
06:45am, Tuesday, 22'nd Apr 2025
MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 202
